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1. Introduction 
All multicellular organisms require a continuous homeostatic control of cellular 
proliferation and differentiation in order to maintain the numbers of the different types of 
cells and the global size of the organism, while at the same time compensating for all the 
permanent loss of cells due to aging and to the attacks from the environment. In general, 
this control is achieved by the use of a hierarchical system where a small number of 
multipotential, slow-dividing, stem cells give rise to more differentiated, actively 
proliferating intermediate progenitors, which in turn will originate large numbers of cells 
committed to a specific cellular fate. These cells will then terminally differentiate and 
integrate functionally into the mature organs or tissues. Along this process there is a 
gradient of developmental potential, in such a way that, as they mature into a certain fate, 
the cells lose the capacity of giving rise to other cell types. 
This process is tightly controlled by extrinsic environmental signals (either permissive or 
inductive) and, more importantly, by the intrinsic transcriptional and epigenetic profiles of 
the developing cells. These profiles change and evolve along with development and are the 
responsibles for establishing both the cellular identity and the susceptibility of the cell to 
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alterations that might alter the outcome of cellular differentiation. The nature of these 
alterations can be environmental (new signals) or, more frequently, internal to the cells 
(genetic or epigenetic alterations). In this context, it is therefore easy to understand that any 
deregulation of the transcriptional or epigenetic equilibrium will lead to an unwanted final 
outcome, like it is the case in tumors, were the cellular identity is reprogrammed by 
oncogenic alterations to give rise to a new pathological lineage. This aberrant deviation of 
the normal developmental program is only possible if the initial cell suffering the oncogenic 
insults posses enough plasticity so as to be reprogrammed by them. In this chapter we 
describe the nature of physiological plasticity, its biological necessity for normal 
development and its underlying molecular and cellular mechanisms, to put them afterwards 
into the context of tumor development. In order to do this, and before discussing the 
concepts in depth, we need to first define the terminology used and to be aware of its 
historical origin within the discipline of developmental biology. 
Physiological plasticity is here defined as the capacity of cells (stem or differentiated) to 
adopt the biological properties (gene expression profile, phenotype, etc.) of other 
differentiated types of cells (that may belong to the same or different lineages). Competence 
(potency) would therefore be a specific manifestation of plasticity, defined as the ability of 
undifferentiated cells (stem cells and progenitors) to give rise to their different descendant 
lineages during normal development (i.e. not pathologically- or experimentally-induced). 
We group both concepts under the same umbrella (plasticity) since it is increasingly clear 
that the same mechanisms involved in stem cell competence during normal development 
are involved in the plasticity of more differentiated types of cells, not only in pathological 
conditions like tumorigenesis, but also in experimentally-induced fate-changing processes. 
In the last years, many advances have been made in our understanding of the biology of 
cellular plasticity (Graf and Enver, 2009; Gurdon and Melton, 2008; Hochedlinger and 
Jaenisch, 2006; Vicente-Duenas et al., 2009a). However, the molecular bases of stem cell 
competence (i.e. plasticity) maintenance or entry into the differentiation programs are not 
yet completely understood (Niakan et al., 2010). 
Competence (potency) as we have defined it above is only one of the main properties that 
define stem cells. The other is their self-renewal capacity, determined by their ability to 
undergo the asymmetric cell divisions that allow them to maintain themselves in an 
unchanged state and, at the same time, to generate daughter cells that enter into the 
differentiation/proliferation cascade (Ward and Dirks, 2007). In this way, when the stem cell 
divides asymmetrically, it gives rise to a new identical stem cell and a multipotential 
progenitor/precursor that will originate all the variety of differentiated cells. When the 
division is symmetrical, two identical daughter cells are created that either retain the same 
stem properties of the mother cell or start the differentiation program, losing the self-
renewal capability and their stem cell properties.  
What we have outlined are the main features of normal development of stem-cell based 
tissues in physiological conditions. However, these processes can be deregulated by many 
different mechanisms, both experimentally in the laboratory and in numerous pathologies, 
like cancer or developmental abnormalities. In all these cases, cellular reprogramming is the 
cause, but the consequences can be very different depending on the triggering mechanisms 
and the plasticity of the initiating cell. As we will discuss in the next section, our 
understanding of the biology of development has increased enormously in the last half 
century, and many different processes have been described in diverse organisms in different 
laboratories. This has also created a great deal of confusion in the scientific nomenclature, 
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and many of the terms commonly used have different meanings for different authors in 
different fields (for example, researchers working in different model organisms), in some 
cases more restrictive, in some more wide-ranging. In this chapter, besides the terms that we 
have already defined, we will use the following terminology (Figure 1): 
- “Dedifferentiation”: the mechanism by which the normal developmental program is 
reverted in such a way that differentiated cells give rise to more plastic, earlier 
progenitors. 
- “Transdifferentiation” designs the direct conversion (reprogramming) of a 
differentiated cell type into another different mature cell, without the need of 
dedifferentiating to earlier developmental stages; it usually involves the passage 
through cellular intermediates that are non-physiological and share markers that are 
normally mutually exclusive, corresponding to the initiating and the final cell. As we 
will discuss later, induced pluripotency would be a particular case of 
transdifferentiation, rather than being a dedifferentiation process, due to the existence 
of those non-physiological intermediates.  
- “Commitment”: the point of no return in physiological development, where the cell 
irreversibly enters a specific differentiation program. For a stem cell, it implies the loss 
of self-renewal. 
- “Epigenetic”: the inheritance of patterns of gene expression, without affecting the 
genetic code itself. In other words, the inheritance that is not codified in the DNA 
sequence. From the molecular point of view, it designs all the chromatin modifications 
that establish (and determine the propagation of) the different possible patterns of 
gene expression of a given, unique genome. 
- “Reprogramming”: from the cellular point of view, the natural or experimentally-
induced alteration of the differentiation program of a given cell. From the molecular 
point of view, all the molecular changes (i.e., epigenetic) that take place in a cell that is 
changing its identity. Dedifferentiation and transdifferentiation are types of 
reprogramming, usually experimentally-induced. Oncogenesis is also a form of 
reprogramming, in this case one that spontaneously happens in nature. 
- “Cancer Stem Cells” (CSCs): the cells responsible for the maintenance, propagation, 
metastasis and relapse of tumors. They posses self-renewal and differentiation 
capabilities and can give rise to all the cellular types that compose the tumor mass. 
Also named cancer-maintaining-cells. 
- “Cancer cell-of-origin”: the normal cell that first suffers the oncogenic hit and initiates 
the tumoral process. It is usually the one giving rise to the CSC. It can be either a 
differentiated cell or a stem/progenitor cell. 
2. Historical perspective  
Since the beginning of human history, men have looked for the ideal of eternal youth, and the 
myths about regeneration of diseased organs (or even resurrection) are among the oldest of 
mankind (Odelberg, 2004). The Egyptian god Osiris had his body resurrected and recomposed 
after having been torn into pieces and thrown in the Nile. The Hydra from the Greek 
mythology could regenerate its multiple heads when they were severed, and only by burning 
the stumps could Hercules defeat the creature. Also, as a punishment for revealing the secret 
of fire to the humans, Prometheus was chained to the mountain where an eagle ate his entrails, 
which would regenerate every new day. All these imaginary creatures have a reflection in the 
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natural world, and this was also observed in very ancient times, and already Aristotle (384-322 
BC) reported that lizards regenerated their tails. But only in the Age of Enlightenment will this 
aspect of the natural world become the matter of scientific study. In 1712, Réamur reports the 
regeneration of the limbs and claws of crayfish (Reaumur, 1712); in 1744, Trembley discovers 
that the two halves of the Hydra polyp can regenerate a whole new organism (hence its name) 
(Trembley, 1744); in 1769, Spallanzani describes how tadpoles can regenerate their tails and 
salamanders can regrow amputated limbs, tails and jaws (Spallanzani, 1769). During most of 
the 19th and first half of the 20th centuries, research was mainly focused in the description of 
these processes from the morphological point of view (Birnbaum and Sanchez Alvarado, 2008; 
Odelberg, 2004). Nevertheless, the detailed analyses performed already showed that, in order 
for the regenerative process to take place, the cells that are normally forming part of the organs 
are not enough, and a special type of cells are required: the progenitor cells. The origin of the 
latter was at that time unclear; in some cases, like for the regeneration of skin, blood, muscles 
or bones, progenitors are shown to exist in the tissues in small numbers, and to become 
activated as a consequence of the lesions. In other cases, the progenitors seem to arise from 
differentiated cells that change their developmental program and become dedifferentiated. 
The best example of this mechanism is observed in urodeles, a group of very primitive 
vertebrates (salamanders, newts, axolotls). In them, once the lesion has occurred, cells from the 
normal tissues form a pool of proliferative progenitors known as the regenerative blastema 
(Bodemer and Everett, 1959; Chalkley, 1954; Hay and Fischman, 1961). These cells will in turn 
give rise to all the tissues in the new limb/tail. This extraordinary example of cellular plasticity 
has been almost completely lost in more evolved vertebrates. Amphibians also provided the 
first animal model of experimentally-induced reprogramming when, in 1952, Briggs and King 
managed to generate frog tadpoles by transplanting the nucleus of cells from the blastula into 
Xenopus oocytes, reverting cellular differentiation (Briggs and King, 1952). Afterwards, 
Gurdon showed that also differentiated cells could be reprogrammed by using nuclei from 
intestinal epithelia cells as donors (Gurdon, 1962). These milestone findings clearly indicated 
that the genetic potential of cells did not diminish during differentiation, and that there were 
no genetic changes occurring during development. The final proof that this principle extends 
also to mammals was the cloning of Dolly the sheep by Wilmut and colleagues in 1997 
(Wilmut et al., 1997). This was the definitive proof that the changes that happen during 
differentiation are fully reversible, demonstrating that the fate restrictions that occur during 
normal development are the result of epigenetic modifications. These studies also showed that 
there were factors in the oocyte cytoplasm capable of reverting the epigenetic program and 
inducing a reprogramming that led to the appearance of a totipotent phenotype. 
The search for the reprogramming factors followed a parallel route. In 1987 it was shown 
that ectopic expression of the Antennapedia homeotic gene lead to changes in the body plan 
of Drosophila, that got extra legs instead of antennae (Schneuwly et al., 1987). Later it was 
found that the ectopic expression of eyeless controlled the full gene cascade responsible of 
eye development and could lead to the formation of ectopic eyes in Drosophila legs (Gehring, 
1996). In mammals, the first master regulatory transcription factor identified was MyoD, 
which could transdifferentiate fibroblasts into the myogenic lineage (Davis et al., 1987). 
Other examples of these reprogramming events dependent on single factors are the 
transdifferentiation of mouse B cells into macrophages by C/EBPα (Xie et al., 2004) or the 
dedifferentiation of committed B cells by the loss of Pax5 (Cobaleda and Busslinger, 2008; 
Cobaleda et al., 2007a; Nutt et al., 1999). All these data proved that the alteration of the 
transcriptional profile by just one factor could cause stable fate changes, and provided the 
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rationale for the search of the factors capable of reprogramming to full pluripotency that led, 
in 2006, to the identification by Takahashi and Yamanaka of the four transcription factors 
capable of inducing pluripotency in terminally differentiated cells (Takahashi and 
Yamanaka, 2006), as we will describe with more detail in the following sections.  
On the other side, cancer has also been known since the origins of mankind. The first 
references are the Edwin Smith and Ebers papyri from the 3000 BC and 1500 BC, 
respectively (Hajdu, 2004). The Edwin Smith papyrus contains the first description of breast 
cancer, with the conclusion that there is no treatment for the disease. Cancer was not so 
prevalent in ancient times, since life span was much shorter, but it was already clearly 
identified. Hippocrates (460–375 BC) noted that growing tumors occurred mostly in adults 
and they reminded him of a moving crab, which led to the terms carcinos and cancer. Celsus 
(25 BC–AD 50) also compared cancer with a crab, because it adheres to surrounding 
structures like if it had claws; he introduced the first classification for breast carcinoma and 
recommended surgical therapy. However, he already noted that tumors could only be cured 
if removed at early stages because, even after excision and correct healing of the scar, breast 
carcinomas could recur with swelling in the armpit and cause death by spreading into the 
body. Galen (131–AD 200) already advised surgery by cutting into healthy tissue around the 
border of the tumor (Hajdu, 2004). If we make a 2000-year leap to our days, it seems 
disappointingly surprising how little those old critical findings have been overcome by 
modern medicine. Indeed, for solid tumors, still today clean surgical margins and lack of 
lymph node invasion are the most important prognostic markers, and only if tumors are 
resected completely before spreading (something that it is anyway impossible to ascertain 
with current technologies) can curation be guaranteed. Much more is what we have learnt in 
the last thirty years about the molecular biology of the disease. In 1979 it was shown that the 
phenotype of transformed cells could be transferred to normal fibroblasts by DNA 
transfection (Shih et al., 1979). In 1982 the molecular cloning of the first human oncogene 
was reported simultaneously by several groups (Goldfarb et al., 1982; Lane et al., 1982; 
Parada et al., 1982; Santos et al., 1982), to be soon identified as the RAS gene. Since then, 
many genes have been described as oncogenes or tumor suppressors, and the molecular 
basis of their transforming activities have been described to great detail. A comprehensive 
study of this topic falls out of the scope of this chapter, but there are some aspects that must 
be taken into account for further posterior discussion. One of them is that, for many types of 
tumors, specific mutations have been described to be tightly associated to the tumor 
phenotype, especially in the case of mesenchymal tumors caused by chromosomal 
aberrations (Cobaleda et al., 1998; Sanchez-Garcia, 1997). This association already suggested 
that the oncogenic aberrations might be acting as new specification factors that determine 
the tumor appearance and/or phenotype. In 2000, Hanahan and Weinberg summarized the 
main features that needed to be disrupted in normal cellular behavior in order for allow a 
tumor to appear and progress (Hanahan and Weinberg, 2000). These main aspects are 
related with the survival and proliferation of cancer cells. However, much less attention has 
been paid to the aspects related to the differentiation. In fact, if cellular fate was carved into 
stone, cancer would be impossible, since no new lineages could be generated other than the 
normal, physiologic ones. Here is where the normal mechanisms regulating cellular identity 
and plasticity play an essential role in allowing cancers to arise and hopefully, as we will 
discuss, they might be the key to its eradication. 
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Fig. 1. The road from developmental plasticity to cancer. Development is here 
conceptualized as a pool ball rolling towards different directions depending on the strokes it 
has received. For simplicity, the pool table is flat and horizontal, but in reality the shape of 
the “developmental terrain” also is an essential contribution to fate determination (see text). 
A) In normal development, fate is established once the initial impulse has been provided by 
internal transcription factors or external signals, and then the cell develops “lineally” 
towards this fate. B) Transdifferentiation. The introduction of a new driving force (cue nº 2, 
for example a transcription factor) redirects the cell towards a new fate, pushing it out of its 
normal route. C) Dedifferentiation. An inversion of the normal process of development, 
following the same differentiation intermediates that were followed in the first instance, but 
in a reversed order. Here, an opposite driving force is depicted (cue nº 2) but this reversion 
could also be due to a lack of initial impulse (i.e., lack of an essential driving transcription 
factor).  
www.intechopen.com








D) Induction of pluripotency. Again, an external force (Yamanaka factors, for example) 
counteracts programmed development and sends the cell back to a progenitor condition, 
but in this case going through non-physiological cellular intermediates. E) Reprogramming. 
After pluripotency has been induced as depicted in the previous panels, the cells can be 
redirected towards new fates with the help of external of internal stimuli (cue nº 3). F) 
Tumorigenesis. An oncogenic hit (cue nº 2), hitting the right cellular intermediate with the 
right strength and angle sends the cell down to a new developmental program that will lead 
to the development of a tumour. According to this view, many of the second hits in 
tumorigenesis (nº 3, 4, 5) are already implicit given the first hit and the nature of the cell. 
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3. Molecular bases of plasticity  
As we have mentioned before, differentiation has been traditionally considered as an 
irreversible process. It was more than 50 years ago when Conrad Waddington 
conceptualized the irreversibility of cellular differentiation as marbles falling down a slope 
(Waddington, 1957). This conceptual and very graphical image has been afterwards widely 
used to visually depict the meaning of transdifferentiation, dedifferentiation or pluripotent 
reprogramming (Hochedlinger and Plath, 2009), all of them “uphill” processes that must 
overcome natural barriers to take place. Interestingly enough, this conceptual view has been 
given a new meaning by the studies of the gene regulatory networks (GRNs) that control 
differentiation; from the mathematical analysis of the interactions among all the genes that 
are expressed in a cell in a certain moment, a geometric description of the developmental 
potential is obtained. In this way, a “landscape” of developmental probabilities is generated 
(Enver et al., 2009; Huang, 2009; Huang et al., 2009) in which “valleys” represent the 
different cellular fates, connected through “slopes” or “channels”, that are the 
differentiation routes. It is important to realize that, in this conceptualization, the landscape 
is in fact defined by the gene expression pattern of the cell itself, not something external to 
it. In this landscape, pluripotency would be a “basin of attraction” situated at the top of a 
peak. Pluripotency therefore behaves like a mathematical attractor, a metastable state 
maintained by small variations in the levels of expression of transcriptional and epigenetic 
regulators. The cells would slide towards the most stable configuration through the slopes, 
and those primed to differentiate would be located at the edge of the “attractor basin”. 
Therefore, the stemness of a cellular population is a metastable equilibrium defined by the 
gene interactions at the level of each individual cell and, consequently, each cell has a 
different intrinsic developmental potential. So, the stem cell condition is not static, but 
rather is a continuum that moves within certain boundaries. For example, in the case of the 
established stem cell marker Sca-1 it has been shown that, in a clonal population of 
progenitor cells, there is a Gaussian distribution of its levels of expression (Chang et al., 
2008). But these cells are not confined to a specific level of expression, as cells at both ends of 
the levels of expression can, with time, recapitulate the whole population with the complete 
range of expression levels. Furthermore, these sub-compartments present different 
transcriptomes that confer them distinct intrinsic developmental tendencies towards diverse 
lineages. These results indicate that each individual cell is an intermediate in a continuum of 
fluctuating transcriptomes. This range of variation is at the basis of the stochastic choice of 
lineage (Chang et al., 2008). The study of a different marker, Stella, in this case in embryonic 
stem (ES) cells, has provided similar findings (Hayashi et al., 2008). Stella is a marker of 
stem cell identity that shows a mixed expression in ES cells, demonstrating that they are not 
uniform, but rather represent a metastable state between intracellular mass- and epiblast-
like states while retaining pluripotency. This equilibrium can be shifted in response to 
several factors, like for example epigenetic regulators (Hayashi et al., 2008). 
The heterogeneous expression of phenotypic markers can be extended to the much more 
significant level of the transcription factors. Phenotypic heterogeneity is a known 
characteristic of progenitors at the population level, and it has been long known that they 
present a promiscuous activation of lineage-associated genes (Hu et al., 1997). Also the 
genes that are associated with the maintenance and specification of the pluripotent state 
vary in the population. In this context, recent results (Kalmar et al., 2009) show that Nanog 
levels experience random fluctuations within the ES cell population, giving rise to two 
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different compartments: one stable, with high levels of Nanog expression, and another much 
more unstable, with low levels of Nanog, and much more prone to differentiate and lose 
pluripotentiality (Kalmar et al., 2009). With the examples that we have provided, we can see 
that pluripotency is a state of dynamic heterogeneity of a population, and it is at the same 
type maintained and driven towards differentiation by fluctuations in the levels of 
expression of transcriptional and epigenetic regulators. The cells that are in the centre of the 
attractor “basin” are less prone to differentiate than the ones approaching the “edge” of the 
“basin”. The latter are already primed to differentiate, so that commitment is a spontaneous 
but rare phenomenon, unless it is elicited by external signals that disrupt the metastable 
equilibrium (Enver et al., 2009; Huang, 2009). This dynamic view explains the duality 
between the simultaneous plasticity and heterogeneity of multipotent populations, and also 
how the balance between instructed and stochastic cell fate decisions takes place.  
4. Loss of plasticity during normal development  
As we have already mentioned, through the normal developmental processes that allow 
stem and primitive progenitor cells to become differentiated, and as a result of physiological 
plasticity, the identity of the cells change and new fates are adopted. These events occur in a 
progressive manner, in such a way that several distinct cell intermediates are generated with 
more restricted potential until the final mature, specialized cell types are generated and 
functionally integrated into the tissues and organs. Each lineage is characterized by a 
defined gene expression profile, resulting of the action of transcription factors and 
epigenetic modifications in a certain cellular environment. We have described how the stem 
cell state is that of a metastable equilibrium that can be disrupted towards differentiation 
either by random intracellular noise variation or by the induction by extracellular signals. 
Once the stem cells start the differentiation process, they begin to make reciprocally 
excluding lineage choices controlled by cross-antagonism between competing transcription 
factors, in such a way that different transcription factors, controlling different subsets of 
genes associated with specific lineages, are also controlling their activities in a reciprocal 
manner, maintaining an equilibrium that can easily be skewed towards one or the other side 
by external signals (Loose et al., 2007; Swiers et al., 2006). With the advent of flow cytometry 
and its capacity to separate cells according to defined combinations of surface markers, the 
study of the development of the hematopoietic system has provided enormous insight into 
the molecular and cellular mechanisms of lineage commitment. Indeed, their peculiar 
characteristics have allowed the isolation and purification of many distinct differentiation 
intermediates, making developmental haematopoiesis the ideal field of research to explore 
the mechanisms of lineage commitment and plasticity. From there, the developmental 
models identified have been extrapolated to other experimental systems, usually with great 
success. The above-described cross-antagonism model can therefore also be found in the 
development of the haematopoietic system. For example, the interaction between the 
transcription factors GATA-1 and PU.1 in myeloid progenitors, where they reciprocally 
inhibit each other and therefore create a binary decision situation for the progenitor that 
must choose between erythroid/megakaryocyte or myeloid-monocytic fates (Enver et al., 
2009; Laiosa et al., 2006). This equilibrium creates a third intermediate condition defined by 
the balance between the expressions of both factors, which would correspond to a bipotent 
progenitor condition. This model has also been found to apply in other systems, like the 
early fate choice of pancreatic progenitors between endocrine and acinar cell lineages, in this 
www.intechopen.com
 Cancer Stem Cells Theories and Practice 
 
12 
case under the control of cross-repressive interactions between the transcription factors 
Nkx6 and Ptf1a (Schaffer et al., 2010). So, in non-committed progenitors there are basal 
levels of parallel expression of opposed transcription factors; this explains the occurrence of 
multilineage gene priming, initially described in haematopoietic stem and progenitor cells 
(Enver et al., 2009; Hu et al., 1997). However, either in in vitro or in vivo settings many 
different developmental intermediates have been described by different groups, and there is 
still a lot of controversy about the exact steps that are really followed in normal 
development, because all experimental systems are imperfect and, like it happens to 
particles in Heisenberg´s uncertainty principle, the mere isolation of the cells already affects 
their developmental potential, and the conditions under which this potential is studied are 
also to a certain degree dictating the possible outcomes. Nevertheless, it is generally 
accepted that there is a hierarchical loss of developmental potential in a gradual progression 
through many serial differentiation options in such a way that, at any point, a progenitor 
would only have to choose between two mutually exclusive options (Brown et al., 2007; 
Ceredig et al., 2009). Afterwards, and to mature towards terminally differentiated cells, the 
progenitors will have to interact with the suitable extrinsic signals (like the cytokines, for 
example) that would for that reason carry out a more permissive than instructive function.  
Although this process is mainly governed by transcription factors, epigenetic modifications 
occur in a progressive manner that modify the chromatin in different ways and help in 
stabilizing expression patterns and their transmission to daughter cells. These epigenetic 
memory systems involve mainly chromatin regulators of the Trithorax and Polycomb group 
proteins, and are in charge of maintaining cell-type-specific expression patterns in many 
developmental systems (Ringrose and Paro, 2004, 2007). For many years these epigenetic 
marks were considered irreversible (in parallel with differentiation), but the most recent 
findings are revealing that they are much more dynamic than initially thought and that they 
contribute greatly to the competence of progenitors. Along these lines, the so-called bivalent 
chromatin regions have been found in embryonic stem (ES) cells, that correspond to genome 
sections simultaneously marked by H3K27me3 (a repressive mark) and H3K4me3 (an 
activating one), and it has been proposed that these domains work by controlling 
developmental genes in these cells while keeping them poised for activation or deactivation, 
suggesting a chromatin-based mechanism for pluripotency maintenance (Bernstein et al., 
2006; Mikkelsen et al., 2007; Sharov and Ko, 2007). The resolution of the bivalent domains 
into either a permanent ‘on’ or ‘off’ state is closely related to the commitment of the cell. 
Initially it was thought to be restricted only to progenitors and only related with genes that 
had to be kept silent and then activated. However, it seems that bivalent domains also can 
appear in differentiated cells like T cells (Roh et al., 2006) and seem to provide a way to 
postpone either the activation or the repression of a functionally distinct group of genes, 
mainly developmental transcription factors (Pietersen and van Lohuizen, 2008). The fact that 
epigenetic modifications themselves are much more flexible than previously thought fits 
very well with the increasing examples of plasticity during development. Indeed, a rigid 
model based on irreversible molecular modifications of the chromatin cannot accommodate 
all the different processes of differentiation, and it is especially difficult to reconcile with 
developmental systems in which terminal differentiation steps require an extensive 
reprogramming of the gene expression profiles with respect to the ones existing in previous 
partially differentiated cellular intermediates. In these systems in which the so-called 
mature cells should still maintain a high degree of plasticity (i.e., a certain degree of 
“stemness”) a different molecular mechanism must exist to make such quick 
reprogramming possible.  
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As a way of an example to illustrate the above-mentioned points, and how developmental 
plasticity plays a role in both normal and pathological differentiation we are going to 
describe the development of a system that has been very well characterized: B cells in the 
hematopoietic system. In the adult, the generation of mature B cells begins with the 
hematopoietic stem cells (HSCs) in the bone marrow (BM). HSCs will be gradually restricted 
towards the B lymphocyte lineage through several stages of differentiation. Initially they 
give rise to multipotent progenitors (MPPs), which have lost the self-renewal capacity but 
retain multilineage differentiation potential. After that, they generate lymphoid-primed 
multipotent progenitors (LMPPs) that already lack erythroid and megakaryocyte potential 
(Adolfsson et al., 2005). LMMPs give rise to early lymphocyte progenitors (ELPs) 
characterised by the activation of recombination-activating genes (Igarashi et al., 2002); these 
will afterwards differentiate into common lymphoid progenitors (CLPs) with potential 
already restricted to B, T and NK pathways (Hardy et al., 2007; Kondo et al., 1997). The 
expression of the transcription factor Pax5 determines definitive commitment to the B cell 
lineage at the pro-B cell developmental stage (see below). Rearrangements of 
immunoglobulin heavy and light chain genes lead to the generation of immature B cells in 
the bone marrow, expressing a functional B cell receptor (BCR) in their surface (IgM) (Jung 
et al., 2006). These immature B cells leave the bone marrow and travel to the peripheral 
lymphoid organs where they become mature B cells (Hardy and Hayakawa, 2001). 
However, mature B cells in the periphery are not in fact, regardless of their name, the last 
differentiation stage of their lineage, because they are in fact waiting for an external signal 
(the antigen recognition) to experience the terminal differentiation process that will result in 
the generation of antibody-producing plasma cells. So, in response to T cell-dependent 
antigens, a dedicated structure, the germinal centre (GC) is formed, where B cells undergo 
several cycles of proliferation, somatic hypermutation, immunoglobulin class switching and 
selection. Positively selected GC B cells can then either become terminally differentiated 
plasma cells or memory cells (Klein and Dalla-Favera, 2008). However, the gene expression 
program of plasma cells is very different to the one of B cells and, in fact, for many genes it 
shows similarities with the expression profile of progenitors (Delogu et al., 2006; Shaffer et 
al., 2002; Shapiro-Shelef and Calame, 2005). So this is an example of a case where the 
terminal differentiation involves a complete reprogramming of the transcriptional profile of 
the previous developmental stage. Clearly, in a system like this plasticity must be 
guaranteed in the late differentiation stages to allow for the last reprogramming step to 
occur, even if a progressive limitation of developmental options takes place together with 
differentiation. This last step of terminal differentiation to plasma cells would not be 
possible if the epigenetic marking of activated and repressed genes that have been 
established during lineage specification was irreversible. Therefore, a mechanism must exist 
for the maintenance of B cell identity that allows this identity to be lost for terminal 
differentiation. In order to understand the molecular basis for this process we must first 
describe the mechanisms that establish and maintain B cell characteristics.  
In uncommitted hematopoietic progenitors, as we have described, plasticity (competence) is 
based on their capacity to maintain a promiscuous level of basal expression of lineage-
specific genes in the process of multilineage priming (Akashi et al., 2003; Hu et al., 1997). 
This promiscuous gene expression pattern allows the progenitors to respond to 
environmental signals that, in combination with the right transcription factors, will lead 
them into the different specific lineages. In the case of B cells, this signalling is provided by 
IL7, in combination with the transcription factors E2A, EBF1 and PAX5 (Cobaleda and 
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Busslinger, 2008; Cobaleda et al., 2007b; Miller et al., 2002; Nutt and Kee, 2007). Although 
the precise roles of this transcription factors in these very early stages is still the subject of 
active investigation, it seems that E2A and EBF1 are in charge of activating the expression of 
B lymphoid genes at the beginning of B cell development. However, the real commitment to 
the lineage is controlled by PAX5. PAX5 is a transcription factor whose expression within 
the haematopoietic system is restricted to B cells. Due to its protein structure it has the dual 
capacity of acting either as a transcriptional activator or as a repressor, depending on the 
interacting partners (Czerny et al., 1993; Dorfler and Busslinger, 1996; Eberhard and 
Busslinger, 1999; Eberhard et al., 2000). Induced by Ebf, Pax5 commits cells to the B cell 
lineage and maintains B cell identity by concurrently repressing B-lineage-inappropriate 
genes and activating B-cell specific genes (Delogu et al., 2006; Schebesta et al., 2007). Once 
Pax5 expression has been initiated, progenitors lose their potential and are only able to 
differentiate along a unidirectional path towards mature B cells. In Pax5 knockout mice 
(Nutt et al., 1999; Urbanek et al., 1994) B cell development cannot progress beyond the pro-B 
cell stage. However, since they are not yet committed, Pax5-/- proB cells behave as 
multipotent progenitors, because they express multilineage genes (that would have been 
otherwise repressed by Pax5 in normal conditions), and this allows them to be programmed 
into most of the haematopoietic lineages under the right conditions. All these 
developmental options are shut down by the reintroduction of Pax5, which actively 
represses all non-B cell genes (Nutt et al., 1999). 
But the role of Pax5 is not over once commitment has taken place; quite the opposite, it is 
continuously required to maintain B cell identity and function all the way through the life of 
the B cell (Cobaleda et al., 2007b). Actually, deletion of Pax5 at different B cell developmental 
stages by using a conditional Pax5 allele has shown that its loss leads to the loss of B cell 
identity and commitment. In proB cells, loss of Pax5 causes committed B cells to recover the 
capacity to differentiate into macrophages and T cells, proving that Pax5 is required not only 
to initiate the B cell program, but also to maintain it in early B cell development (Mikkola et al., 
2002). Deletion of Pax5 at later stages of B cell development results in the loss of mature B cells, 
inefficient lymphoblast formation, and reduced IgG formation. Most B cell membrane antigens 
are downregulated, and the transcription of B cell-specific genes is decreased, whereas the 
expression of non-B cell-specific genes is activated (Horcher et al., 2001; Schebesta et al., 2007). 
Thus, mature B cells radically change their gene expression pattern in response to Pax5 
inactivation. These effects can be easily understood when considering that Pax5 activates at 
least 170 genes that are essential for B cell signalling, adhesion, migration, antigen 
presentation, and germinal-centre B cell formation (Schebesta et al., 2007), indicating that Pax5 
controls in a direct manner both B cell development and function. In the absence of Pax5, all 
this network collapses and the cells lose their B cell identity. The loss of B-cell specific genes 
upon Pax5 deletion goes together with the loss of Pax5-dependent repression of non-B cell 
genes. Derepression of these genes (around 110 genes controlling functions such as receptor 
signalling, cell adhesion, migration, transcriptional control, and cellular metabolism (Delogu et 
al., 2006)) unveils a new plasticity for peripheral Pax5-deleted mature B cells: they can 
dedifferentiate in vivo back to early uncommitted multipotent progenitors in the bone marrow, 
which can afterwards give rise to other haematopoietic cell types like macrophages or T cells 
(Cobaleda et al., 2007a). 
This Pax5-dependent plasticity has a biological reason and is directly related with the 
physiology of B cells. As we already mentioned, the final function of mature B cells is to 
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become plasma cells. For this terminal differentiation to take place, Pax5 must be 
downregulated, to permit the closing down of all the B cell transcriptional program (Delogu 
et al., 2006; Schebesta et al., 2007; Shapiro-Shelef and Calame, 2005) and allow the transition 
to the plasma cell stage. The process starts with the binding of the membrane BCR to its 
cognate specific antigen. This activates a signalling cascade that leads to the upregulation of 
Blimp1, the master regulator of the plasma cell transcriptional program and identity (Kallies 
and Nutt, 2007; Martins and Calame, 2008). Mature B cells and plasma cells have very 
different gene expression programs, which are controlled in a mutually exclusive manner by 
Pax5 and Blimp1, respectively. In fact, Pax5 is directly repressed by Blimp1, as a way of 
eliminating B cell identity and allowing for plasma cell differentiation to proceed (Lin et al., 
2002). The expression of many Pax5-activated genes is either absent or considerably reduced 
upon Pax5 loss in plasma cells, and Pax5-repressed genes are reexpressed in plasma cells 
(Delogu et al., 2006). Many of the genes that are expressed in plasma cells are also expressed 
in uncommitted lymphoid progenitors (Delogu et al., 2006). But, since these genes are not 
compatible with B cell development or function they must be silenced to maintain B cell 
identity. However, as they will be required for terminal differentiation into plasma cells, 
they cannot be irreversibly repressed in B cells by stable epigenetic modifications. The 
molecular mechanism underlying this versatility is based on the function of Pax5: first, it 
preserves B cell identity, and afterwards it allows for a simple mechanism (repression of 
Pax5) of eliminating this identity when reprogramming becomes necessary to generate a 
plasma cell. This is the reason why mature B cells retain such a high degree of plasticity 
dependent on a single gene. 
This mechanism that we have outlined for B-cell differentiation is present in other systems 
and can explain the existence of plasticity in many other developmental models. For 
instance, in the process of melanocyte differentiation from adult melanocyte stem cells, the 
transcription factor Pax3 initiates a melanogenic program and, simultaneously, prevents 
downstream terminal differentiation (Lang et al., 2005). Pax3-expressing melanoblasts are 
therefore committed, but remain undifferentiated until Pax3-mediated repression is 
relieved. Hence, also in this example a transcription factor can simultaneously determine 
cell fate and maintain an undifferentiated state, leaving a cell poised to differentiate in 
response to external stimuli. This molecular mechanism implies a high degree of cellular 
plasticity, since the elimination of the factor(s) responsible allows the cells to readily 
differentiate to other lineages. Perhaps the most striking example of this plasticity is the 
reprogramming of adult mouse ovaries into testes induced by the removal of transcription 
factor Foxl2 (Uhlenhaut et al., 2009). In a fascinating result, the deletion of this single, organ-
identity-maintaining gene leads to the full conversion of all the female ovary tissues into 
their male ontological equivalents, showing that cellular (and even organ) plasticity can be 
much less hidden than we think, and that cell (and organ) identity can be maintained by just 
a single gene (Uhlenhaut et al., 2009). 
5. Experimental control of plasticity: reprogramming  
In the previous sections we have described the different levels of physiological plasticity 
that can be found during normal development, and shown that they are in fact necessary for 
differentiation to occur. However, we have also seen that this plasticity is usually not 
manifested spontaneously, but is rather something latent in the cells that we can only reveal 
in an artificial way. As a general rule, the ultimate cellular identity of any particular 
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differentiation pathway is stable and typically corresponds to a very specialized cellular 
type with a highly specific physiological function. Therefore, on paper, plasticity, from the 
point of view of normal development, is a property that should in principle be limited to 
stem cells and progenitors (i.e. cells that require this competence for their function). This 
could be called the physiological plasticity, that is, the normal competence of progenitors 
that we have previously discussed. All other types of cells should remain stable and 
maintain their identity. Indeed, most reprogramming cases occur either “on purpose” in the 
lab (experimental reprogramming for regenerative medicine) or in an “accidental” manner 
in nature (reprogramming in tumorigenesis, see below). However, this notion of stability 
was seriously challenged by the results for Yamanaka´s group showing that, and least in an 
experimental setting in the laboratory, reprogramming specialized cells to pluripotency only 
required the action of four factors (or even less): the 4 transcription factors from Yamanaka: 
Oct4, Sox2, c-Myc and Klf4 (Takahashi and Yamanaka, 2006). This finding showed in a 
definitive manner that there is a latent developmental potential retained in the cell, and 
what are the factors required to unleash it. The knowledge of reprogramming as a reality 
was already present, as we have mentioned before, in the results from the seminal nuclear 
reprogramming from the 1950-60s (Briggs and King, 1952; Gurdon, 1962). However, even 
though it was since then obvious that a cell nucleus could be converted from the program of 
a differentiated cell into that of a pluripotent progenitor just by being transferred into the 
right cytoplasmic environment, it was difficult to imagine that only a few of factors were 
really required to make the entire process possible. We have also seen that the gain and/or 
loss of single, essential, factors can alter the whole developmental program of a cell.  
In the laboratory, there are several experimental approaches to achieve cellular 
reprogramming that might lead to pluripotency. On one side, there is nuclear transfer, 
where the whole nucleus is taken away from one cell and transferred into a new one, a 
previously enucleated oocyte whose cytoplasms contains all the factors required to impose 
an multipotential state. Although this method does not involve the acquisition of genetic 
changes, obviously the whole nuclear environment is changed, with all the possible 
consequences that this may have (Byrne et al., 2007; Gurdon and Melton, 2008; 
Hochedlinger and Jaenisch, 2006). Another possibility for reprogramming is cellular fusion, 
which allows the nuclei of a cell to act over that of another cell and therefore, under the 
appropriate circumstances, alter fate (Yamanaka and Blau, 2010). Exogenous expression of 
transcription factors was one of the first ways of demonstrating how reprogramming could 
take place (see Section 2), in this case without reverting cells back to a pluripotent stage 
(Zhou and Melton, 2008a). Some examples include transdifferentiation of adult pancreatic 
exocrine cells to β cells after expression of the transcription factors Ngn3, Pdx1 and Mafa 
(Zhou et al., 2008; Zhou and Melton, 2008a, b), the conversion of fibroblasts into myogenic 
cells by the myogenic factor MyoD (Davis et al., 1987) and the transdifferentiation of 
committed B lymphocytes to macrophages by expression of C/EBPα (Xie et al., 2004). The 
identification of the right cocktail of factors led to the reprogramming to pluripotency 
(induced-pluripotency stem cells, iPSCs) by the introduction of stem cell-specific genes into 
a differentiated cell (Maherali et al., 2007; Okita et al., 2007; Takahashi and Yamanaka, 2006; 
Wernig et al., 2007). This can be done by introducing genetic changes in the treated cells or 
in a less invasive, transient way, using specific drugs or transient vectors (Abujarour and 
Ding, 2009; Mikkelsen et al., 2008; Stadtfeld et al., 2008a; Stadtfeld et al., 2008b).  
Another possibility of exploiting physiological plasticity for experimentally-induced 
reprogramming is to eliminate the specific transcription factors (usually master regulators) 
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responsible for maintaining the identity and function of the differentiated cell and for 
keeping its epigenetic state. This, as we have seen, leads to a lineage reprogramming into 
new cell types like in the case of the conversion of mature B cells into T cells (Cobaleda and 
Busslinger, 2008; Cobaleda et al., 2007a).  
Of all these methods, nuclear transfer is empirical, but all the other ones require a precise 
knowledge of the transcriptional and epigenetic machineries that control the identities of the 
starting cellular material and the final desired product. It is very clear now that, together 
with the specific activation or repression of transcription factors (usually master regulators 
of specific lineages), the epigenetic modifications are an indispensable part of the process, 
since they are the ones that define the “flexibility” of the cell to be reprogrammed. As we 
have mentioned before, in general, differentiated cells correspond to a highly specialized 
compartment with no plasticity. According to this fact, it has been recently described that in 
the haematopoietic system the HSCs are 300 times more prone to reprogramming than B or 
T cells (Eminli et al., 2009). 
Since the differentiated state is the more stable one, a certain level of “activation energy” is 
required to move the cells “uphill” to become again pluripotent. From this point of view of 
inducing pluripotency, there are two possibilities (Yamanaka, 2009): i) either only some cells in 
the population can be reprogrammed, because they are the ones that are responsive to the 
reprogramming factors (elite model), or ii) all the cells are equally susceptible to 
reprogramming (stochastic model). The latest evidences indicate that the second possibility 
happens to be true and that, given the appropriate combination of stimuli (in this case, the 
reprogramming factors), any cell can be reprogrammed to change fate (Hanna et al., 2009), and 
that the process can be accelerated either by interfering with the DNA damage checkpoint (see 
below) or by increasing the expression of some of the reprogramming factors, like Nanog 
(Hanna et al., 2009). The global inefficiency of the reprogramming process, even in the most 
favourable conditions, clearly suggests that, independently of the initial number of cells that 
are actually responsive to the reprogramming factors, very few of them can finally achieve full 
reprogramming. It has been shown that factor-induced reprogramming is a gradual process 
with several more or less defined cellular intermediates (Stadtfeld et al., 2008a). Some of these 
non-physiological reprogramming intermediates (remember our definition of 
transdifferentiation) can be isolated as cell lines stuck at some point of the conversion process 
(Mikkelsen et al., 2008). The study of these incompletely reprogrammed intermediates shows 
that they have re-activated stem cell renewal and maintenance genes, but those genes in 
charge of pluripotency are still repressed. Also, the cells have not been able of completely 
repressing the expression of lineage-specific transcription factors. On top of that, these cells 
have failed in completing epigenetic remodelling and still retain persistent DNA 
hypermethylation marks (Mikkelsen et al., 2008). 
6. Cancer: the dark side of plasticity  
We have shown that plasticity is an essential feature of development. However, as all 
aspects of normal physiology, it also represents a “weakness” that can give rise to the origin 
of diseases. As we have mentioned, cancer is a differentiation disease, and tumorigenesis 
represent the outcome of a deviation of the normal process of differentiation in which a new 
lineage, the tumour, is created, with new properties and characteristics, but still similar in 
some ways to normal lineages. In other words, cancer could be considered as a particular 
case of “wrong” reprogramming. 
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In the last decade great advances have been made in our understanding of the cellular 
origin of cancer. Many of these findings have been driven by the postulation and final 
coming of age of the theory of the cancer stem cells (CSCs). It is beyond of the scope of this 
chapter to detail all the aspects and implications of this theory, which have been previously 
discussed to great extent (Cobaleda et al., 2008; Cobaleda and Sanchez-Garcia, 2009; Lobo et 
al., 2007; Reya et al., 2001; Sanchez-Garcia et al., 2007; Vicente-Duenas et al., 2009a), so here 
we will limit our discussion to the aspects related to cellular plasticity and differentiation. 
The CSC theory proposes that tumours are heterogeneous tissues, maintained by tissue-
specific stem cells, in a manner very similar to any other stem cell-based tissue in the 
organism. Therefore in any tumour, different types of cells coexist: some of them are 
differentiated cells, lacking the possibility of propagating cancer, and that normally 
constitute the main mass of the tumour. However, there is also a variable, but generally 
small, percentage of cancer stem cells (CSCs), which are defined by the fact that they are the 
only ones that posses the capacity of replenishing the tumour mass and of transplanting the 
cancer (Castellanos et al., 2010; Greaves, 2010; Hermann et al., 2010; Lane and Gilliland, 
2010; Sanchez-Garcia, 2010; Shackleton, 2010; Vicente-Duenas et al., 2010). Therefore, if 
cancer is a stem-cell driven tissue, it becomes crucial to identify the first cell suffering the 
oncogenic alteration(s) i.e., the normal cell that will give rise to the cancer stem cell, and the 
mechanisms that are behind this fate reprogramming. This first cell, as previously defined, 
would be the cancer cell-of-origin. What is clear is that the initiating cell’s intrinsic plasticity 
must allow the cell to be reprogrammed into the new tumoral type(s). So cellular plasticity 
and the responsiveness of the cell to the reprogramming effects of the oncogene are 
therefore critical factors in the tumorigenesis process, and this implies that specific cancer-
inducing alterations happen in particular cells (stem or differentiated, see below), and that it 
is the reciprocal interaction between the cellular plasticity and the differentiating capabilities 
of the oncogenic event(s) what determines the final resultant tumor phenotype. 
From the point of view of the nature of the oncogenic alteration(s) and its potential 
reprogramming capabilities, traditionally in the field of cancer research it was assumed that 
more than one hit was required to switch from a normal healthy cell into a tumoral one, 
implying that many different aspects of cellular biology must be altered in the progress to 
final tumorigenesis (Hanahan and Weinberg, 2000). Also in the field of plasticity it was 
consequently assumed that, to convert a certain cell into a different one, more than one 
single alteration was required. This was partially supported for a long time by the fact that 
the only way to achieve full reprogramming to pluripotency was nuclear transplantation, a 
purely empirical method in which it was impossible to isolate or identify the factors 
responsible for the stem state. This seemed to suggest that many elements were necessary 
for reprogramming to occur. In fact, as we have discussed before, for “simple” changes in 
identity, like it could be a transdifferentiation process, a single, transcription factor could be 
all that is required to induce the reprogramming, as long as it is the right factor for the right 
type of cell (Cobaleda et al., 2007a; Davis et al., 1987; Nutt et al., 1999; Xie et al., 2004). This 
was similar as how a single initial oncogenic lesion may only cause an alteration in 
proliferation, or a partial block in differentiation. The breakthrough of Takahashi and 
Yamanaka (Takahashi and Yamanaka, 2006) showed that only 4 transcription factors (“four 
hits”) were necessary for induction of pluripotency. Of note, the 4 transcription factors have 
been shown to play an oncogenic role in different contexts, and both c-Myc and Klf4 are 
well-known oncogenes (Chen et al., 2008; Okita et al., 2007; Rowland et al., 2005; Tanaka et 
al., 2007). This is a clear evidence of the essential mechanistic link between reprogramming 
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and cancer, and illustrates the fact that there are a certain number of genes/proteins that are 
strong enough so as to induce the change of expression patterns in a global manner affecting 
cellular identity. Only strong regulators of the transcriptional and/or epigenetic machineries 
can reprogram. Therefore, the multistep nature of tumorigenesis can be compared with the 
series of developmentally unfavoured “uphill” steps required for full reprogramming to 
pluripotency. All these barriers are biologically designed to protect cells from 
transformation, that is, to prevent cells from changing their identity. There are many articles 
and reviews describing the capacity that the different oncogenes have for blocking or 
interfering with essential cellular functions (Hanahan and Weinberg, 2000). In the case of the 
reprogramming factors our knowledge is still incomplete, but the answers are gradually 
arising from the study of partially reprogrammed states and also by introducing the 
different factors at different times during the process of induction of pluripotency, starting 
from mouse fibroblasts (Sridharan et al., 2009). This kind of experiments has allowed 
showing that the different factors have temporal and separable contributions during the 
reprogramming process. In the initial stages, and previously to the induction of the ES-cell-
like gene expression program, silencing of the somatic cell gene expression program takes 
place, mainly due to the action of c-Myc, although it is not yet clear how this gene mediates 
repressive effects in this context. Nevertheless, it has previously been shown that histone 
deacetylase inhibitors like valproic acid (VPA) can partially substitute for c-Myc in the 
reprogramming process (Huangfu et al., 2008) (see below) collaborating in the repression of 
the differentiated cells’ gene program. Therefore, it would seem that c-Myc mostly acts 
before the pluripotency regulators are activated and, consequently, ectopic expression of c-
Myc is only required for the first few days of reprogramming (Sridharan et al., 2009). 
Actually, it seems that c-Myc could be dispensable for reprogramming, but in its absence 
there is a massive decrease in the efficiency of the process (Nakagawa et al., 2008; Wernig et 
al., 2008). It seems that the other factors, Oct4, Sox2, and Klf4, need to act together in 
establishing the pluripotent condition, since they cannot associate with their target genes in 
cells that are only partially reprogrammed, most probably because the histone methylation 
pattern does not allow their binding (Sridharan et al., 2009). This correlates with our 
knowledge about the function of these factors in ES cells, were they bind cooperatively to 
hundred of genes in overlapping genomic sites (Boyer et al., 2005; Loh et al., 2006), acting in 
a coordinated manner to maintain the transcriptional program required for pluripotency. 
However, even though the four Yamanaka factors can be sufficient for reprogramming most 
cell types, there are cases where they are not enough. One of the most striking examples is 
precisely that of B cells. In mature B lymphocytes, the four factors cannot achieve full 
reprogramming, and another molecular manipulation is required: the extinction of Pax5 
expression (Hanna et al., 2008). As we have mentioned before, the elimination of Pax5 by 
itself is all what is required for mature B cells to dedifferentiate to early multipotential 
progenitors, since Pax5 is the responsible for the initiation and maintenance of B-cell 
identity and function (Cobaleda et al., 2007a). So the presence of such a strong factor 
requires its specific elimination in order to achieve reprogramming. These results also 
connect reprogramming to tumorigenesis, since it had previously been described that the 
loss of cellular identity induced by the absence of Pax5 led to the development of tumours 
or an early-B cell progenitor phenotype (Cobaleda et al., 2007a), indicating that the loss of 
the identity of the initial cell is an essential step in tumorigenesis. In fact, a very similar 
observation has been made in human patients with the uncommon transdifferentiation of 
follicular B cell lymphoma (FL) into a myeloid histiocytic/dendritic cell (H/DC) sarcoma 
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(Feldman et al., 2008). The FL and H/DC tumors of each patient are clonally related, since 
they contain the same immunoglobulin rearrangements and an identical IgH-BCL2 
translocation breakpoint. It has been suggested that the translocation-induced 
overexpression of BCL2 leads to a prolonged survival of FL B that can facilitate their loss of 
B-lineage identity and subsequent reprogramming into H/DC tumor cells (Feldman et al., 
2008). There are more examples corroborating the fact that loss of cell identity is essential for 
tumoral reprogramming. For example, in human Hodking lymphomas the inactivation of 
the B cell factor E2A by overexpression of its specific antagonists activated B cell factor 1 
(ABF-1) and inhibitor of differentiation 2 (Id2) leads to the loss of B cell markers and 
expression of lineage-inappropriate genes that characterizes the tumour pathognomonic 
Reed-Sternberg cells (Mathas et al., 2006). Another aspect worth mentioning is the fact that, 
in contrast to mature B cells, earlier B cell developmental stages could be reprogrammed to 
pluripotency just with the four Yamanaka factors (Hanna et al., 2008), again underscoring 
the idea that the degree of differentiation of the target cell impacts directly in the 
reprogramming efficiency. 
An essential component of both the reprogramming process and tumoral progression are 
epigenetic changes. It is clear that cancer does not only depend on genetic mutations, but 
also on epigenetic changes that establish a new pattern of heritability, providing a cellular 
memory by which the new tumoral cellular identity can be maintained, and that these 
alterations constitute an essential part of cancer initiation and progression (Ting et al., 2006). 
The role of epigenetic alterations in tumour origin and progression is well known and it has 
been comprehensively reviewed elsewhere (Esteller, 2007, 2008; Esteller and Herman, 2002). 
All epigenetic marks become altered in tumours, leading to changes in gene expression. 
These changes have been very well described to affect many specific genes in charge of 
controlling cellular functions, which therefore become altered in cancer. But these changes 
are in fact global and affect the whole cellular identity. The tumour-related epigenetic 
alterations can either be independent from the initiating oncogenic mutation and simply due 
to tumour progression, or they can be directly linked to the first oncogenic event, like it 
happens in the case of chromosomal translocations that affect histone-modification genes 
(Esteller, 2008). In the case of reprogramming to pluripotency, something similar happens, 
since epigenetic modifications are an intrinsic part of the process and they need to take place 
in a global manner, not just by the specific regulation of some individual genes that is 
mainly accomplished by the transcription factors. This explains why the efficiency of 
reprogramming increases greatly in the presence of chemicals interfering with epigenetic 
marks in an unspecific (i.e., not locus-restricted) manner. For example, treatment with 5-aza-
cytidine (AZA), a DNA methyltransferase inhibitor, induces a rapid transition to fully 
reprogrammed iPSCs (Huangfu et al., 2008; Mikkelsen et al., 2008), and the use of valproic 
acid (VPA), a histone deacetylase (HDAC) inhibitor, greatly improves the induction to 
pluripotency (Huangfu et al., 2008). Treatment with the inhibitor of the G9a 
methyltransferase named BIX-01294 increases the efficiency of reprogramming using just 
two factors, Oct4 and Klf4, to levels similar to the ones achieved when using the four factors 
(Shi et al., 2008). G9a methyltransferase is essential for the extinction of the pluripotency 
program upon exit to differentiation because, by means of its histone methylation activity, it 
blocks target-gene reactivation in the absence of transcriptional repressors, and this leads to 
the silencing of embryonic genes like Oct4 (Feldman et al., 2006). Also, simultaneously, G9a 
promotes DNA methylation, and therefore prevents the reprogramming to the 
undifferentiated state (Epsztejn-Litman et al., 2008; Feldman et al., 2006). All these facts 
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support the idea that global epigenetic changes affecting a large and unknown number of 
genes are a critical selective component of the reprogramming process, and that the addition 
of chemicals that facilitate these molecular changes helps the process by lowering the 
activation energy barrier for this “uphill” process. A very important practical consequence 
of these findings is the fact that epigenetic therapies are already in use or in very advanced 
clinical trials against cancer. Their mechanisms of action are based on the assumption that, 
by globally affecting epigenetic patters of tumoral cells, they can restore the normal levels of 
expression of genes that are required for the normal control of cellular proliferation and/or 
differentiation. Like for any other chemotherapy, the effects are systemic, but it is likely to 
affect primarily the tumoral cells and leave non-proliferative cells relatively unaffected. 
Since 2004, AZA is FDA-approved as the first drug of the new class of demethylating agents 
for the treatment of myelodysplastic syndromes (Kaminskas et al., 2005), and there are 
many other clinical trials evaluating the effects of AZA in other cancer types (Sacchi et al., 
1999). Something similar happens with HDAC inhibitors (Dey, 2006; Lane and Chabner, 
2009). All these findings emphasize once more the nature of cancer as a pathological case of 
“wrong” reprogramming, as a differentiation disease. 
As we have seen, both the changes in the epigenetic patterns and the gain or loss of 
transcriptional regulators are essential components of the tumour generation and of the 
experimentally-induced reprogramming processes. It is clear that these alterations, although 
based in mechanisms normally existing in the cells, are undesirable for normal cellular 
development and functioning, so the cells have evolved a series of safety mechanisms to 
avoid these alterations or their effects and maintain their identity and function. In the 
context of cancer there have been many studies in the last decades describing how all these 
safety mechanisms are bent, broken or bypassed to allow tumour generation and 
progression (Hanahan and Weinberg, 2000). The most recent results in the less advanced 
field of reprogramming seem to indicate that, also in this experimentally-induced 
“progression to pluripotency” (in analogy to tumoral progression) exactly as it happens in 
tumour progression, the elimination of the DNA damage control checkpoint tremendously 
increases the efficiency of the reprogramming process. Thus, the inactivation of the p53-p21 
axis by different approaches allows a much higher percentage of the starting cells to 
successfully complete the process to full pluripotency (Banito et al., 2009; Hong et al., 2009; 
Kawamura et al., 2009; Krizhanovsky and Lowe, 2009; Li et al., 2009; Marion et al., 2009; 
Utikal et al., 2009; Zhao et al., 2008) . However, this enhanced efficiency is achieved at the 
price of a much higher genetic instability, and the iPSCs generated in this way carry many 
genetic aberrations of different types. This is corresponding to the facts that we have 
previously mentioned showing that reprogramming is an “uphill”, developmentally 
unfavourable process that imposes a great stress to the cells and that most of the cells 
therefore, in normal conditions, fail to complete (Mikkelsen et al., 2008). These results do not 
only further support the idea of cancer as a disease of cellular differentiation but, 
furthermore, indicate that indeed, the aberrant transcription factors, deregulated signalling 
molecules and epigenetic regulators are the main dynamic forces behind the tumoral 
process, and that many of the other alterations (for example, loss of p53) play just a 
permissive role for tumoral progression. 
We have until now examined the processes of reprogramming and tumorigenesis mainly 
from a molecular point of view. The inclusion of epigenetics in our description encompasses 
to a certain degree cellular identity, since the epigenetic pattern of chromatin modifications 
can be broadly assimilated to cellular identity. However, in the next final paragraphs we are 
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going to discuss the tumoral reprogramming phenomenon from a more classical cellular 
point of view. In the field of cancer research it has conventionally been assumed that the 
phenotype of the tumoral cell was a mirror of the one of the normal cell from which it arose. 
Most tumour cells present the characteristics of differentiated cell types (more or less 
aberrant). Therefore, for every type of tumour, the cell of origin had to be found in its closest 
relative in the normal tissue. However, the solidification of the cancer stem cell (CSC) theory 
has led to a re-thinking of these concepts (Cobaleda and Sanchez-Garcia, 2009; Vicente-
Duenas et al., 2009b). First, since tumours are postulated to be stem cell-based tissues, not all 
the tumoral cells are equally capable of regenerating the tumour, but only those cells with 
CSC properties. Most of the cells lack this capacity, although there can be great variations in 
the percentage of CSCs within a tumour. This has important repercussions for our 
understanding of tumour origin. If tumours are maintained by aberrant cells with the 
characteristics of stem cells, then where do these cells come from? The cancer cell-of-origin 
would therefore be a normal cell that has undergone reprogramming by the oncogenic 
events to give rise to a CSC, a new pathological cell with stem cell properties. One 
possibility is that the oncogenic mutations take place in a normal stem cell that, in this way, 
becomes reprogrammed to originate the new pathological tissue. This has been long known 
to be the case for chronic myelogenous leukaemia (CML), where the causing chromosomal 
translocation t(9;22) is present in most lineages of differentiated haematopoietic cells, thus 
indicating that an early progenitor is the cell of origin (Melo and Barnes, 2007). Recent 
advances in modelling human diseases in the mouse have allowed us to prove this fact 
experimentally; indeed, restricting the oncogenic alteration to the stem cell compartment in 
the mouse is all that is required to generate a full CML with the whole variety of 
differentiated cells (Perez-Caro et al., 2009; Vicente-Duenas et al., 2009b). Also for intestinal 
cancers it has been proven in mice that they have their origin in the crypt stem cells, by 
activating the Wnt signalling pathway specifically in the stem cell compartment. This leads 
to the generation of adenomas where a differentiation hierarchy is maintained. On the 
contrary, if the oncogenic lesions are targeted to the non-stem, more differentiated intestinal 
epithelial cells, only small, short-lived microadenomas appear (Barker et al., 2008; Zhu et al., 
2008). In other tissular context, targeting astrocytoma-associated oncogenic lesions to the 
nervous system progenitors results in tumour development, whereas targeting them to the 
zone containing just differentiated cells only gives rise to local astrogliosis (Alcantara 
Llaguno et al., 2009). In all these and other similar cases (Dirks, 2008; Joseph et al., 2008; 
Zheng et al., 2008) it is therefore clear that the initiating event must take place in a stem cell, 
even if, afterwards, the macroscopic tumour is composed by differentiated cells. This 
indicates a pathological direct reprogramming mediated by the oncogenic lesions.  
The other alternative is that of the cancer cell-of-origin being a differentiated cell type. In 
this case the cells must be reprogrammed not only towards a new fate, but also to regain 
stem cell characteristics in a process of tumoral reprogramming to pluripotency. For this to 
occur, two aspects have to come together: first, the oncogenic alteration must be capable of 
conferring the stem properties and, second, the cell must have a degree of plasticity that 
allows the reprogramming mediated for this specific alteration to take place. It has been 
shown that some oncogenes, like MOZ-TIF2 (Huntly et al., 2004), MLL-AF9 (Krivtsov et al., 
2006; Somervaille and Cleary, 2006), MLL-ENL (Cozzio et al., 2003), MLL-GAS (So et al., 
2003) or PML-RARα (Guibal et al., 2009; Wojiski et al., 2009) can generate CSCs when they 
are introduced into target cells that were already committed. Some of these genes, like MLL-
AF9, have been shown to be able of activating a stem cell-like self-renewal program in 
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already committed progenitors (Krivtsov et al., 2006). A somewhat comparable situation 
happens with c-Myc, which can induce some parts of the transcriptional program of an 
embryonic stem cell in differentiated epithelial cells, thus giving rise to epithelial CSCs 
(Wong et al., 2008). Other oncogenes, like BCR-ABLp190, are however unable of conferring 
self-renewal properties (Huntly et al., 2004). In these cases, self-renewal must be provided 
by the target cell or by additional alterations, so that the oncogene does not immediately 
generates a CSC, but rather originates a precancerous cell that can afterwards give rise to a 
true CSC (Chen et al., 2007). In any case, the exact cellular origin of the initiating lesions is 
very difficult to determine, especially since, in many cases, the functional impact of the 
lesion, the clonal expansion, can become apparent only by the generation of cells that can be 
either upstream or downstream of the initiating cell, at least in terms of phenotypic markers. 
For example, in several childhood B acute lymphoblastic leukaemias (ALL) the initiating 
translocations originate prenatally in utero and act in partially committed cells as a first-hit 
capable of conferring this preleukaemic cell with aberrant self-renewal and survival 
properties (Hong et al., 2008). In AML1-ETO leukaemias, the translocation can still be 
detected in patients in remission, indicating that the cells can remain latent and some of 
their descendants can become tumorigenic with time (Miyamoto et al., 2000). In children’s B-
ALLs, the CSC properties can be found in blasts of more than one different developmental 
stage, which can also interconvert among themselves (le Viseur et al., 2008). This obviously 
makes the determination of the nature of the cancer-cell of origin even more difficult. Also 
in ALLs, the comparison of relapsed patient samples with the samples obtained from the 
same patients at their diagnosis by means of genomic analysis has shown that both initial 
and relapsed tumours share the same ancestral clone (Mullighan et al., 2008) that had 
diverted in different manners during the different stages of the disease. So, the nature of the 
CSC evolves over time with disease progression, treatment and relapse, in such a way that 
the properties of the CSC population in a certain moment do not necessarily reflect the 
nature of the initial cancer cell-of-origin (Barabe et al., 2007).  
In the context of reprogramming to pluripotency, the initiating factors are not necessary 
anymore once the cells are already iPSCs and the process has been completed, that is to say, 
when the new identity has been fixed and the cell is already in a new pluripotent “attractor 
basin”. If cancer stem cells arose through a reprogramming-like mechanism then, as a 
logical consequence, maybe the oncogenes initiating tumour formation might be 
dispensable for the posterior stages of tumour development (Krizhanovsky and Lowe, 
2009). This fact correlates well with the examples of the subsistence of a pre-cancerous lesion 
in a stable population of cells that are already aberrant, but need secondary hits to initiate 
the openly tumoral differentiation program. In this way, the initiating lesion would have an 
active function in the reprogramming process, but afterwards it would become just a 
passenger mutation, or even perform a different function in tumour development that could 
very well be independent from its initial reprogramming activity. This could clarify the lack 
of success of some current targeted therapies, like the anti-BCR-ABL kinase drug imatinib 
which, although successfully eliminates differentiated tumour cells, fails to kill the BCR-
ABL+ CSCs (Barnes and Melo, 2006; Graham et al., 2002; Perez-Caro et al., 2009; Vicente-
Duenas et al., 2009b). From a mathematical modeling point of view and consistent with the 
gene regulatory network (GRN) approaches, the oncogenic mutations alter one of the nodes 
and therefore change the architecture of the network, thus leading to a change in the 
landscape topography and giving rise to new abnormal attractors (new “valleys”) where 
cancer stem cells are trapped (Huang et al., 2009). This modeling also fits with the above-
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discussed postulate that a cell can stay in the new attractor even after the stimulus that 
triggered the transition has already disappeared, implying that the transient expression of 
an oncogene can be enough to trigger a lasting malignant phenotype that can become 
independent for its maintenance on the originating mutation (Huang et al., 2009). 
7. Future prospects  
Cancer is the second cause of mortality in the developed countries and its incidence is 
quickly rising in the Third World too. Current treatments for cancer are still focused in the 
idea of tumours as diseases in which the normal processes of proliferation are altered and 
consequently, therapies are targeted against proliferating cells. All these treatments are 
therefore unspecific and highly toxic, particularly for the non-cancerous cells in the 
organism with highly proliferation rates (epithelia, hair...). The most recent research 
advances have shown that cancer must be considered to a great degree as a disease of 
differentiation in which a new tissue, the tumour, emerges from cells that, following an 
oncogenic event, acquire new pathological fates. So it follows that cancer is a disease that, at 
least in its initial stages, is closely linked to reprogramming. Therefore, the research in 
reprogramming is intimately tied to that in cancer.  
Considering cancer as a reprogramming disease gives us a new point of view over the 
disease in our search for new therapeutic strategies. Differentiation therapies are already in 
use for some very specific cases of cancer (e.g., differentiation of PML-RARα-positive acute 
promyelocytic leukaemias with the use of retinoic acid). Reprogramming to pluripotency 
also gets stuck at in the “uphill” way to pluripotency (Mikkelsen et al., 2008) and it is very 
probable that tumoral cells are very similar to these partially reprogrammed intermediates, 
whose study should help us to learn how to force tumour cells out of their blocked 
condition. This is in fact what is planned to achieve with the use of the newest epigenetic 
drugs that are already approved or close to approval for treatment of specific tumours. 
Along the way we are also progressively learning more about the molecular mechanisms 
that govern epigenetic marks, and this knowledge about the epigenetic control of self-
renewal, differentiation and maintenance of identity should help us to obtain more 
specifically targeted epigenetic therapies (Jones, 2007). 
Our increasing knowledge and control over the mechanisms programming cellular identity 
should make us able of developing strategies to reprogram cancer cells in different ways. It 
has already been shown that it is possible to use nuclear transplantation approaches to 
reprogram melanoma cells (Hochedlinger et al., 2004) embryonal carcinomas (Blelloch et al., 
2004) and even to clone mouse embryos from brain tumours (Li et al., 2003). All these 
findings indicate that it can be perfectly feasible to reprogram tumour cells. Hopefully in a 
near future we will possess the scientific and technological knowledge so as to be able of 
modifying tumoral cell fate at will to reprogram them either by forcing them to differentiate 
and disappear or to become susceptible to new therapies. 
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